← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
The Institute For Cancer Research
$24,185,499
Total funding
40
Grants
Funding over time
peak $4.8M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$24,185,499 · 40
By mechanism
—$24,185,499 · 40
Investigators at The Institute For Cancer Research
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
PEMBROLIZUMAB MAINTENANCE AFTER ENFORTUMAB VEDOTIN/PEMBROLIZUMAB INDUCTION IN FRONT-LINE METASTATIC UROTHELIAL CARCINOMA.$1,959,353
· FY2025 · Defense Health Agency
IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON QUALITY OF LIFE AND TREATMENT-RELATED DECISION-MAKING IN ADVANCED PROSTATE CANCER$1,402,500
· FY2022 · Defense Health Agency
OVERCOMING RESISTANCE TO EGFR INHIBITORS IN ADVANCED HEAD AND NECK CANCERS$1,402,500
· FY2021 · Defense Health Agency
DELINEATING THE ROLE OF THE ACETYL-COA PATHWAY IN THE RESISTANCE TO ANTI-ANDROGEN THERAPY$1,368,836
· FY2022 · Defense Health Agency
IDENTIFYING DETERMINANTS OF PARP INHIBITOR SENSITIVITY IN OVARIAN CANCER$1,294,124
· FY2014 · Department of Defense
ELIMINATING METASTATIC TRIPLE-NEGATIVE BREAST CANCER THROUGH FERROPTOSIS$1,166,127
· FY2019 · Defense Health Agency
EXAMINING THE RELATIONSHIP BETWEEN COMMUNITY HISTORY AND PROSTATE CANCER DISPARITIES$982,480
· FY2022 · Defense Health Agency
DECIPHERING BRAIN STROMA-REGULATED IMMUNE MICROENVIRONMENT IN MELANOMA BRAIN METASTASIS MOD P00001 INCORPORATED TRANSFER OF AWARD TO INSTITUTE FOR CANCER RESEARCH AND DE-OB FUNDS OF $1,399.04$909,101
· FY2025 · Defense Health Agency
INVESTIGATING PALB2 MUTANT BREAST CANCER$846,000
· FY2024 · Defense Health Agency
THE ROLE OF CDON IN OVARIAN CARCINOMA$803,250
· FY2016 · Department of the Army
INVESTIGATING THERAPEUTIC RESPONSE DISPARITIES IN LOCALLY ADVANCED RECTAL CANCER$752,000
· FY2025 · Defense Health Agency
NF130108: TESTING THE ROLE OF P21 ACTIVATED KINASES IN SCHWANNOMA FORMATION USING A NOVEL GENETICALLY ENGINEERED MURINE MODEL THAT CLOSELY PHENOCOPIE$751,318
· FY2014 · Department of Defense
CANCER-ASSOCIATED MACROPHAGELIKE (CAML) CELLS TO ENHANCE DETECTION OF EARLY-STAGE LUNG CANCER AND RELAPSE AFTER DEFINITIVE TREATMENT$672,969
· FY2018 · Department of the Army
DEVELOPING BIOMARKERS OF RESPONSE TO CHEMORADIATION THERAPY IN RECTAL CARCINOMA: TOWARD PRECISION MEDICINE$658,800
· FY2018 · Department of the Army
IMMUNOLOGIC AND MICROBIAL CORRELATES AND MECHANISMS OF COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER$658,800
· FY2019 · Department of the Army
ENHANCING IMMUNE CHECKPOINT BLOCKADE BY REPROGRAMMING THE METHYLOME WITH NOVEL EPIGENETIC MODULATORS THAT INDUCE A PROINFLAMMATORY RESPONSE$654,500
· FY2021 · Defense Health Agency
THYMINE DNA GLYCOSYLASE AS A NOVEL TARGET FOR LUNG CANCER$624,750
· FY2017 · Department of the Army
TOWARDS PRECISION PREVENTION: TESTING A NOVEL RISK PREDICTION ALGORITHM IN PANCREATIC CANCER$588,346
· FY2017 · Department of the Army
HISTONE-DEPENDENT PARP-1 INHIBITORS: A NOVEL THERAPEUTIC MODALITY FOR THE TREATMENT OF RENAL CELL CARCINOMA$566,149
· FY2018 · Department of the Army
INCREASE CLINICAL TRIAL ENROLLMENT OF UNDERREPRESENTED KIDNEY CANCER PATIENTS BY IMPROVING ACCESS TO PARTICIPATION$564,000
· FY2025 · Defense Health Agency